{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T20:27:19Z","timestamp":1783974439460,"version":"3.55.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Numerous studies have investigated the potential association of sodium-glucose co-transporter-2 inhibitors (SGLT2-Is) with an increased risk of lower limb amputations (LLAs), but have produced conflicting results. Particularly studies comparing SGLT2-Is to glucagon-like peptide-1 receptor agonists (GLP1-RAs) seem to find a higher LLA risk with SGLT2-I use. This raises the question whether the results are driven by a protective GLP1-RA-effect rather than a harmful SGLT2-I-effect. GLP1-RAs could promote wound healing and therefore reduce the risk of LLAs, but the associations between both drug classes and LLA remain uncertain. Therefore, the aim of the current study was to investigate the risk of LLA and diabetic foot ulcer (DFU) with SGLT2-I use and GLP1-RA use versus sulfonylurea use.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective population-based cohort study was conducted using data from the Danish National Health Service (2013\u20132018). The study population (N\u2009=\u200974,475) consisted of type 2 diabetes patients aged 18\u2009+\u2009who received a first ever prescription of an SGLT2-I, GLP1-RA or sulfonylurea. The date of the first prescription defined the start of follow-up. Time-varying Cox proportional hazards models estimated the hazard ratios (HRs) of LLA and DFU with current SGLT2-I use and GLP1-RA use versus current SU use. The models were adjusted for age, sex, socio-economic variables, comorbidities and concomitant drug use.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Current SGLT2-I use was not associated with a higher risk of LLA versus sulfonylureas {adjusted HR 1.10 [95% confidence interval (CI) 0.71\u20131.70]}. Current GLP1-RA use, on the other hand, was associated with a lower risk of LLA [adjusted HR 0.57 (95%CI 0.39\u20130.84)] compared to sulfonylureas. The risk of DFU was similar to that with sulfonylureas with both exposures of interest.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>SGLT2-I use was not associated with a higher risk of LLA, but GLP1-RAs with a lower risk of LLA. Previous studies reporting a higher risk of LLA with SGLT2-I use compared to GLP1-RA use might have been looking at a protective GLP1-RA effect, rather than a harmful SGLT2-I effect.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-023-01897-2","type":"journal-article","created":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T17:02:00Z","timestamp":1688058120000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["The use of sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists versus sulfonylureas and the risk of lower limb amputations: a nation-wide cohort study"],"prefix":"10.1186","volume":"22","author":[{"given":"Nikki C. C.","family":"Werkman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna H. M.","family":"Driessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coen D. A.","family":"Stehouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vestergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaas C.","family":"Schaper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joop P.","family":"van den Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes T. H.","family":"Nielen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,29]]},"reference":[{"issue":"1","key":"1897_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1177\/1938640017694722","volume":"11","author":"DK Wukich","year":"2018","unstructured":"Wukich DK, Raspovic KM, Suder NC. Patients with diabetic foot disease fear major lower-extremity amputation more than death. Foot Ankle Spec. 2018;11(1):17\u201321.","journal-title":"Foot Ankle Spec"},{"issue":"9498","key":"1897_CR2","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/S0140-6736(05)67698-2","volume":"366","author":"AJM Boulton","year":"2005","unstructured":"Boulton AJM, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet. 2005;366(9498):1719\u201324.","journal-title":"Lancet"},{"key":"1897_CR3","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.avsg.2016.12.015","volume":"42","author":"JR Stern","year":"2017","unstructured":"Stern JR, Wong CK, Yerovinkina M, Spindler SJ, See AS, Panjaki S, et al. A Meta-analysis of long-term mortality and associated risk factors following lower extremity amputation. Ann Vasc Surg. 2017;42:322\u20137.","journal-title":"Ann Vasc Surg"},{"issue":"16","key":"1897_CR4","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1056\/NEJMoa1310799","volume":"370","author":"EW Gregg","year":"2014","unstructured":"Gregg EW, Li Y, Wang J, Burrows NR, Ali MK, Rolka D, et al. Changes in diabetes-related complications in the United States, 1990\u20132010. N Engl J Med. 2014;370(16):1514\u201323.","journal-title":"N Engl J Med"},{"issue":"5","key":"1897_CR5","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s00125-008-0940-0","volume":"51","author":"L Prompers","year":"2008","unstructured":"Prompers L, Schaper N, Apelqvist J, Edmonds M, Jude E, Mauricio D, et al. Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE Study. Diabetologia. 2008;51(5):747\u201355.","journal-title":"Diabetologia"},{"issue":"2","key":"1897_CR6","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S2213-8587(13)70050-0","volume":"1","author":"AA Tahrani","year":"2013","unstructured":"Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol. 2013;1(2):140\u201351.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10166","key":"1897_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31\u20139.","journal-title":"Lancet"},{"issue":"27","key":"1897_CR8","doi-asserted-by":"publisher","first-page":"e7201","DOI":"10.1097\/MD.0000000000007201","volume":"96","author":"J Li","year":"2017","unstructured":"Li J, Gong Y, Li C, Lu Y, Liu Y, Shao Y. Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus: a meta-analysis. Medicine. 2017;96(27):e7201.","journal-title":"Medicine"},{"issue":"3","key":"1897_CR9","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s40618-019-01103-9","volume":"43","author":"EG Dorsey-Trevi\u00f1o","year":"2020","unstructured":"Dorsey-Trevi\u00f1o EG, Gonz\u00e1lez-Gonz\u00e1lez JG, Alvarez-Villalobos N, Gonz\u00e1lez-Nava V, Contreras-Garza BM, D\u00edaz Gonz\u00e1lez-Colmenero A, et al. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis. J Endocrinol Invest. 2020;43(3):289\u2013304.","journal-title":"J Endocrinol Invest"},{"issue":"7","key":"1897_CR10","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"11","key":"1897_CR11","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1111\/dom.13424","volume":"20","author":"PB Ryan","year":"2018","unstructured":"Ryan PB, Buse JB, Schuemie MJ, DeFalco F, Yuan Z, Stang PE, et al. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: a real-world meta-analysis of 4 observational databases (OBSER. Diabetes Obes Metab. 2018;20(11):2585\u201397.","journal-title":"Diabetes Obes Metab"},{"key":"1897_CR12","doi-asserted-by":"publisher","first-page":"k4365","DOI":"10.1136\/bmj.k4365","volume":"363","author":"P Ueda","year":"2018","unstructured":"Ueda P, Svanstrom H, Melbye M, Eliasson B, Svensson A-M, Franzen S, et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ. 2018;363:k4365.","journal-title":"BMJ"},{"key":"1897_CR13","doi-asserted-by":"publisher","first-page":"m2812","DOI":"10.1136\/bmj.m2812","volume":"370","author":"M Fralick","year":"2020","unstructured":"Fralick M, Kim SC, Schneeweiss S, Everett BM, Glynn RJ, Patorno E. Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. BMJ. 2020;370:m2812.","journal-title":"BMJ"},{"issue":"10","key":"1897_CR14","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.2337\/dc18-1094","volume":"41","author":"K Dhatariya","year":"2018","unstructured":"Dhatariya K, Bain SC, Buse JB, Simpson R, Tarnow L, Kaltoft MS, et al. The Impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: results from the LEADER trial. Diabetes Care. 2018;41(10):2229\u201335.","journal-title":"Diabetes Care"},{"issue":"12","key":"1897_CR15","doi-asserted-by":"publisher","first-page":"e008018","DOI":"10.1161\/CIRCINTERVENTIONS.119.008018","volume":"12","author":"A Badjatiya","year":"2019","unstructured":"Badjatiya A, Merrill P, Buse JB, Goodman SG, Katona B, Iqbal N, et al. Clinical outcomes in patients with type 2 diabetes mellitus and peripheral artery disease: results from the EXSCEL trial. Circ Cardiovasc Interv. 2019;12(12):e008018.","journal-title":"Circ Cardiovasc Interv"},{"issue":"9","key":"1897_CR16","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/S2213-8587(17)30257-7","volume":"5","author":"GP Fadini","year":"2017","unstructured":"Fadini GP, Avogaro A. SGLT2 inhibitors and amputations in the US FDA adverse event reporting system. Lancet Diabetes Endocrinol. 2017;5:680\u20131.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"1897_CR17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2174\/1574886315666200805103053","volume":"16","author":"NCC Werkman","year":"2021","unstructured":"Werkman NCC, Nielen JTH, van den Bergh JPW, Ejskjaer N, R\u00f8ikjer J, Schaper NC, et al. Use of sodium-glucose co-transporter-2-inhibitors (SGLT2-Is) and risk of lower limb amputation. Curr Drug Saf. 2021;16(1):62\u201372.","journal-title":"Curr Drug Saf"},{"issue":"8","key":"1897_CR18","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1111\/dme.12196","volume":"30","author":"C Bruun","year":"2013","unstructured":"Bruun C, Siersma V, Guassora AD, Holstein P, de FineOlivarius N. Amputations and foot ulcers in patients newly diagnosed with type 2 diabetes mellitus and observed for 19 years: the role of age, gender and co-morbidity. Diabetic Me. 2013;30(8):964\u201372.","journal-title":"Diabetic Me"},{"issue":"5462","key":"1897_CR19","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1126\/science.287.5462.2398","volume":"287","author":"L Frank","year":"2000","unstructured":"Frank L. Epidemiology. When an entire country is a cohort. Science. 2000;287:2398\u20139.","journal-title":"Science"},{"issue":"3","key":"1897_CR20","first-page":"263","volume":"46","author":"TF Andersen","year":"1999","unstructured":"Andersen TF, Madsen M, J\u00f8rgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Danish Med Bull. 1999;46(3):263\u20138.","journal-title":"Danish Med Bull"},{"key":"1897_CR21","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/CLEP.S91125","volume":"7","author":"M Schmidt","year":"2015","unstructured":"Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, S\u00f8rensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449\u201390.","journal-title":"Clin Epidemiol"},{"issue":"7 Suppl","key":"1897_CR22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/1403494810394717","volume":"39","author":"HW Kildemoes","year":"2011","unstructured":"Kildemoes HW, S\u00f8rensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health. 2011;39(7 Suppl):38\u201341.","journal-title":"Scand J Public Health"},{"issue":"6","key":"1897_CR23","doi-asserted-by":"publisher","first-page":"398","DOI":"10.7326\/M18-3079","volume":"170","author":"S Schneeweiss","year":"2019","unstructured":"Schneeweiss S, Rassen JA, Brown JS, Rothman KJ, Happe L, Arlett P, et al. Graphical depiction of longitudinal study designs in health care databases. Ann Intern Med. 2019;170(6):398\u2013406.","journal-title":"Ann Intern Med"},{"key":"1897_CR24","unstructured":"Dansk Endokrinologisk Seslkab. Type 2 Diabetes. https:\/\/endocrinology.dk\/nbv\/diabetes-melitus\/behandling-og-kontrol-af-type-2-diabetes\/. Accessed 30 Nov 2022."},{"key":"1897_CR25","doi-asserted-by":"publisher","first-page":"i1450","DOI":"10.1136\/bmj.i1450","volume":"352","author":"J Hippisley-Cox","year":"2016","unstructured":"Hippisley-Cox J, Coupland C. Diabetes treatments and risk of amputation, blindness, severe kidney failure, hyperglycaemia, and hypoglycaemia: open cohort study in primary care. BMJ. 2016;352:i1450.","journal-title":"BMJ"},{"key":"1897_CR26","unstructured":"World Health Organisation. ATC\/DDD Index. https:\/\/www.whocc.no\/atc_ddd_index\/. Accessed 15 Nov 2022."},{"issue":"12","key":"1897_CR27","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/0895-4356(95)00048-8","volume":"48","author":"P Peduzzi","year":"1995","unstructured":"Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol. 1995;48(12):1503\u201310.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"1897_CR28","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.pcd.2021.12.007","volume":"16","author":"Y Du","year":"2022","unstructured":"Du Y, Bai L, Fan B, Ding H, Ding H, Hou L, et al. Effect of SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists on diabetic foot-related extremity amputation in patients with T2DM: a meta-analysis. Prim Care Diabetes. 2022;16(1):156\u201361.","journal-title":"Prim Care Diabetes"},{"issue":"10365","key":"1897_CR29","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group SiM-AC-RTC","year":"2022","unstructured":"Nuffield Department of Population Health Renal Studies Group SiM-AC-RTC. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400(10365):1788\u2013801.","journal-title":"Lancet"},{"issue":"9","key":"1897_CR30","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1007\/s00125-021-05497-1","volume":"64","author":"DS-H Lin","year":"2021","unstructured":"Lin DS-H, Lee J-K, Chen W-J. Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors. Diabetologia. 2021;64(9):1949\u201362.","journal-title":"Diabetologia"},{"key":"1897_CR31","doi-asserted-by":"publisher","first-page":"m4573","DOI":"10.1136\/bmj.m4573","volume":"372","author":"SC Palmer","year":"2021","unstructured":"Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;372:m4573.","journal-title":"BMJ"},{"issue":"2","key":"1897_CR32","doi-asserted-by":"publisher","first-page":"101325","DOI":"10.1016\/j.diabet.2022.101325","volume":"48","author":"AJ Scheen","year":"2022","unstructured":"Scheen AJ. Lower limb amputations: protection with GLP-1 receptor agonists rather than increased risk with SGLT2 inhibitors? Diabetes Metabol. 2022;48(2):101325.","journal-title":"Diabetes Metabol"},{"key":"1897_CR33","doi-asserted-by":"publisher","first-page":"869804","DOI":"10.3389\/fphar.2022.869804","volume":"13","author":"YC Lee","year":"2022","unstructured":"Lee YC, Dong YH, Yang WS, Wu LC, Lin JW, Chang CH. Risk of major adverse limb events in patients with type 2 diabetes mellitus receiving sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: a population-based retrospective cohort study. Front Pharmacol. 2022;13:869804.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1897_CR34","doi-asserted-by":"publisher","first-page":"7000","DOI":"10.1038\/s41598-021-86516-4","volume":"11","author":"H-Y Chang","year":"2021","unstructured":"Chang H-Y, Chou Y-Y, Tang W, Chang G-M, Hsieh C-F, Singh S, et al. Association of antidiabetic therapies with lower extremity amputation, mortality and healthcare cost from a nationwide retrospective cohort study in Taiwan. Sci Rep. 2021;11(1):7000.","journal-title":"Sci Rep"},{"key":"1897_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05772-9","author":"DS-H Lin","year":"2022","unstructured":"Lin DS-H, Yu A-L, Lo H-Y, Lien C-W, Lee J-K, Chen W-J. Major adverse cardiovascular and limb events in people with diabetes treated with GLP-1 receptor agonists vs SGLT2 inhibitors. Diabetologia. 2022. https:\/\/doi.org\/10.1007\/s00125-022-05772-9.","journal-title":"Diabetologia"},{"issue":"6","key":"1897_CR36","doi-asserted-by":"publisher","first-page":"e0234065","DOI":"10.1371\/journal.pone.0234065","volume":"15","author":"J Heyward","year":"2020","unstructured":"Heyward J, Mansour O, Olson L, Singh S, Alexander GC. Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: a systematic review and meta-analysis. PloS ONE. 2020;15(6):e0234065.","journal-title":"PloS ONE"},{"issue":"9","key":"1897_CR37","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1001\/jamainternmed.2018.3034","volume":"178","author":"H-Y Chang","year":"2018","unstructured":"Chang H-Y, Singh S, Mansour O, Baksh S, Alexander GC. Association between sodium-glucose cotransporter 2 inhibitors and lower extremity amputation among patients with type 2 diabetes. JAMA Intern Med. 2018;178(9):1190\u20138.","journal-title":"JAMA Intern Med"},{"issue":"6","key":"1897_CR38","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.ejvs.2021.09.031","volume":"62","author":"RN Rodionov","year":"2021","unstructured":"Rodionov RN, Peters F, Marschall U, L\u2019Hoest H, Jarzebska N, Behrendt C-A. Initiation of SGLT2 inhibitors and the risk of lower extremity minor and major amputation in patients with type 2 diabetes and peripheral arterial disease: a health claims data analysis. Eur J Vasc Endovasc Surg. 2021;62(6):981\u201390.","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"1897_CR39","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000000000115","author":"EL Fu","year":"2023","unstructured":"Fu EL, D\u2019Andrea E, Wexler DJ, Patorno E, Paik JM. Safety of sodium-glucose cotransporter-2 inhibitors in patients with CKD and type 2 diabetes: population-based US cohort study. Clin J Am Soc Nephrol. 2023. https:\/\/doi.org\/10.2215\/CJN.0000000000000115.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"1897_CR40","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/dom.13477","volume":"21","author":"GK Dawwas","year":"2019","unstructured":"Dawwas GK, Smith SM, Park H. Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes. Diabetes Obes Metab. 2019;21(1):28\u201336.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"1897_CR41","doi-asserted-by":"publisher","first-page":"e00036","DOI":"10.1002\/edm2.36","volume":"1","author":"F Persson","year":"2018","unstructured":"Persson F, Bodegard J, Lahtela JT, Nystr\u00f6m T, J\u00f8rgensen ME, Jensen ML, et al. Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): a multinational observational study. Endocrinol Diabetes Metab. 2018;1(4):e00036.","journal-title":"Endocrinol Diabetes Metab"},{"issue":"5","key":"1897_CR42","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1097\/EDE.0000000000000864","volume":"29","author":"MB Mathur","year":"2018","unstructured":"Mathur MB, Ding P, Riddell CA, VanderWeele TJ. Web site and R package for computing E-values. Epidemiology. 2018;29(5):e45\u20137.","journal-title":"Epidemiology"},{"issue":"4","key":"1897_CR43","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167(4):268\u201374.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1897_CR44","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/(SICI)1096-9136(199801)15:1<80::AID-DIA517>3.0.CO;2-K","volume":"15","author":"CJ McCabe","year":"1998","unstructured":"McCabe CJ, Stevenson RC, Dolan AM. Evaluation of a diabetic foot screening and protection programme. Diabet Med. 1998;15(1):80\u20134.","journal-title":"Diabet Med"},{"issue":"6","key":"1897_CR45","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s00125-019-4835-z","volume":"62","author":"L Potier","year":"2019","unstructured":"Potier L, Roussel R, Velho G, Saulnier PJ, Bumbu A, Matar O, et al. Lower limb events in individuals with type 2 diabetes: evidence for an increased risk associated with diuretic use. Diabetologia. 2019;62(6):939\u201347.","journal-title":"Diabetologia"},{"issue":"1","key":"1897_CR46","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12933-021-01276-9","volume":"20","author":"C Lin","year":"2021","unstructured":"Lin C, Zhu X, Cai X, Yang W, Lv F, Nie L, et al. SGLT2 inhibitors and lower limb complications: an updated meta-analysis. Cardiovasc Diabetol. 2021;20(1):91.","journal-title":"Cardiovasc Diabetol"},{"key":"1897_CR47","doi-asserted-by":"publisher","first-page":"660263","DOI":"10.3389\/fphys.2021.660263","volume":"12","author":"H Huang","year":"2021","unstructured":"Huang H, Wang L, Qian F, Chen X, Zhu H, Yang M, et al. Liraglutide via activation of AMP-activated protein kinase-hypoxia inducible factor-1\u03b1-heme oxygenase-1 signaling promotes wound healing by preventing endothelial dysfunction in diabetic mice. Front Physiol. 2021;12:660263.","journal-title":"Front Physiol"},{"key":"1897_CR48","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jss.2016.09.024","volume":"208","author":"J-N Roan","year":"2017","unstructured":"Roan J-N, Cheng H-N, Young C-C, Lee C-J, Yeh M-L, Luo C-Y, et al. Exendin-4, a glucagon-like peptide-1 analogue, accelerates diabetic wound healing. J Surg Res. 2017;208:93\u2013103.","journal-title":"J Surg Res"},{"issue":"1","key":"1897_CR49","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/atv.0000615456.97862.30","volume":"40","author":"J Helmst\u00e4dter","year":"2020","unstructured":"Helmst\u00e4dter J, Frenis K, Filippou K, Grill A, Dib M, Kalinovic S, et al. Endothelial GLP-1 (glucagon-like peptide-1) receptor mediates cardiovascular protection by liraglutide in mice with experimental arterial hypertension. Arterioscler Thromb Vasc Biol. 2020;40(1):145\u201358.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1897_CR50","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2017.04.001","volume":"261","author":"T Jojima","year":"2017","unstructured":"Jojima T, Uchida K, Akimoto K, Tomotsune T, Yanagi K, Iijima T, et al. Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice. Atherosclerosis. 2017;261:44\u201351.","journal-title":"Atherosclerosis"},{"key":"1897_CR51","doi-asserted-by":"publisher","first-page":"5523","DOI":"10.3402\/dfa.v1i0.5523","volume":"1","author":"A Nather","year":"2010","unstructured":"Nather A, Siok Bee C, Keng Lin W, Qi Odelia KS, Yiong Huak C, Xinyi L, et al. Socioeconomic profile of diabetic patients with and without foot problems. Diabet Foot Ankle. 2010;1:5523.","journal-title":"Diabet Foot Ankle"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-01897-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-023-01897-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-01897-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T18:03:03Z","timestamp":1688061783000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-023-01897-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,29]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1897"],"URL":"https:\/\/doi.org\/10.1186\/s12933-023-01897-2","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,29]]},"assertion":[{"value":"8 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval is not required for register-based studies in Denmark.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"NW has nothing to disclose. JD has nothing to disclose. JN has nothing to disclose. JvB has nothing to disclose. PV is head of research in the Steno Diabetes Center North Denmark funded by the Novo Nordisk Foundation. CS has nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"160"}}